Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Descriptor ID |
D042461
|
MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 3 | 3 |
1997 | 0 | 5 | 5 |
1998 | 0 | 10 | 10 |
1999 | 0 | 17 | 17 |
2000 | 0 | 28 | 28 |
2001 | 0 | 36 | 36 |
2002 | 0 | 44 | 44 |
2003 | 4 | 31 | 35 |
2004 | 25 | 21 | 46 |
2005 | 23 | 29 | 52 |
2006 | 16 | 22 | 38 |
2007 | 20 | 29 | 49 |
2008 | 23 | 30 | 53 |
2009 | 21 | 38 | 59 |
2010 | 20 | 22 | 42 |
2011 | 21 | 25 | 46 |
2012 | 14 | 21 | 35 |
2013 | 21 | 15 | 36 |
2014 | 17 | 22 | 39 |
2015 | 12 | 22 | 34 |
2016 | 11 | 18 | 29 |
2017 | 12 | 18 | 30 |
2018 | 7 | 13 | 20 |
2019 | 8 | 22 | 30 |
2020 | 2 | 20 | 22 |
2021 | 5 | 21 | 26 |
2022 | 1 | 22 | 23 |
2023 | 7 | 25 | 32 |
2024 | 5 | 11 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage. Surv Ophthalmol. 2025 Jan-Feb; 70(1):96-105.
-
Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody. Gene Ther. 2024 Nov; 31(11-12):587-593.
-
Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype. Cells. 2024 Sep 13; 13(18).
-
Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis. Ann Med. 2024 Dec; 56(1):2396559.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
A method for rapid and reliable quantification of VEGF-cell binding activity. Biochem Biophys Res Commun. 2024 10 01; 727:150321.
-
International Classification System for Ocular Complications of Anti-VEGF Agents in Clinical Trials. Ophthalmology. 2024 Dec; 131(12):1457-1467.
-
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol. 2024; 20(30):2241-2248.
-
Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial. Circ Cardiovasc Interv. 2024 May; 17(5):e014054.
-
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.